Extranodal marginal zone b-cell lymphoma of mucosa-associated lymphoid tissue Trials in Columbus, United States

Research into Extranodal marginal zone b-cell lymphoma of mucosa-associated lymphoid tissue spans multiple therapeutic approaches and trial phases.

10 total trials for this combination

Trials

NCT ID	Title	Status	Phase
NCT01129193	AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lymphoma	COMPLETED	PHASE1
NCT01479842	Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma	ACTIVE_NOT_RECRUITING	PHASE1
NCT00293345	3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma	COMPLETED	PHASE1
NCT00112723	Flavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma	TERMINATED	PHASE1/PHASE2
NCT00058227	Alvocidib, Fludarabine Phosphate, and Rituximab in Treating Patients With Lymphoproliferative Disorders or Mantle Cell Lymphoma	COMPLETED	PHASE1
NCT02049541	Study of BKM120 & Rituximab in Patients With Relapsed or Refractory Indolent B-Cell Lymphoma	COMPLETED	PHASE1
NCT00103272	17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hematologic Cancer	TERMINATED	PHASE1
NCT00017472	Monoclonal Antibody Therapy in Treating Patients With Chronic Lymphocytic Leukemia, Lymphocytic Lymphoma, Acute Lymphoblastic Leukemia, or Acute Myeloid Leukemia	COMPLETED	PHASE1
NCT00010192	Rituximab Plus Interleukin-2 in Treating Patients With Hematologic Cancer	COMPLETED	PHASE1
NCT01812005	Alisertib With and Without Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma	TERMINATED	PHASE2